^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB3824

    i
    Other names: TQB3824, TQB 3824
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    CDC7 kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Preclinical candidate TQB3824, a small molecule inhibitor of CDC7, shows strong antitumor efficacy in colorectal and pancreatic tumor models (AACR 2021)
    We have identified a novel potent CDC7 inhibitor TQB3824, which shows high antitumor efficacy in CDC7 overexpressed solid tumor models. TQB3824 represents a promising clinical candidate for treating solid tumors with high CDC7 expression.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • MCM2 (Minichromosome maintenance complex component 2)
    |
    KRAS mutation
    |
    TQB3824